The newly formed Medicinal Cannabis Council Australia (MCCA) has announced its inaugural seven-member board and is progressing with the appointment of its first full-time chief executive officer. The MCCA was established following the merger of two industry bodies, Medicinal Cannabis Industry Australia (MCIA) and the Australian Medicinal Cannabis Association (AMCA), to create a unified representative organisation for the sector.
Inaugural Board Members and Structure
The Medicinal Cannabis Council Australia’s inaugural board comprises seven directors, selected from 18 nominees across various categories. Electronic voting for the positions concluded on Thursday, with the successful candidates announced shortly thereafter, as reported by Cannabiz AU. The board members are:
- Patient Advocate Director: Lucy Haslam
- Industry Directors: Ean Alexander, Phoebe Macleod, Sharon Bentley
- Healthcare Practitioner Directors: Dr Priya Ayyar, Nicholas Ravenswood
- Independent Director: Geoff Bloom
These directors will serve in unpaid positions, consistent with the structure of the former MCIA and AMCA boards. The new board is scheduled to convene soon to appoint its chair and define its strategic priorities for the remainder of 2026. During the transitional period, the MCCA was jointly chaired by Kristin Viccars and Dr Teresa Nicoletti, both of whom have stated they will not seek to continue as chairs once the new board is fully operational.
Dr. Nicoletti noted during a member briefing that this period represents a critical juncture for the sector, particularly regarding potential regulatory reforms. MCCA executive officer Patty Holmes expressed a desire for continuity, hoping that some former MCIA and AMCA board members would be elected to the new board to facilitate a smooth transition for the organisation.
Search for a Full-Time Chief Executive Officer
In addition to establishing its board, the Medicinal Cannabis Council Australia is nearing the appointment of its first full-time chief executive officer. The role attracted 180 applications, which have since been narrowed down to five candidates following initial interviews. The appointment is anticipated within the next two weeks.
The creation of a paid executive team, led by a full-time CEO and supported by staff, marks an operational advancement for the MCCA. While specific remuneration details were not disclosed, Kristin Viccars indicated that salaries for the paid positions are expected to align with market rates. Dr. Teresa Nicoletti highlighted that the availability of funds to appoint a full-time CEO represents a significant development for the sector, enhancing its capacity for dedicated advocacy and operational leadership.
Implications for Australian Medicinal Cannabis
The formation of the Medicinal Cannabis Council Australia and the establishment of its inaugural board, coupled with the imminent appointment of a full-time CEO, are intended to provide a unified and professional voice for the Australian medicinal cannabis industry. This consolidated structure is expected to strengthen the sector’s engagement with regulators, policymakers, and healthcare professionals, potentially influencing future regulatory frameworks and access pathways for medicinal cannabis products in Australia.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
